Coronavirus disease 2019 and lung cancer: where are we?

Autor:	Ocanto A; Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesiCare Madrid, 28002 Madrid, Spain.; Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesiCare Madrid, 28002 Madrid, Spain., Mielgo-Rubio X; Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain., Luna Tirado J; Department of Radiation Oncology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain., Linares Mesa N; Department of Radiation Oncology, Hospital Universitario Juan Ramón Jiménez, 21005 Huelva, Spain., López Valcárcel M; Department of Radiation Oncology, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain., Pedraza S; Department of Radiation Oncology, Hospital Universitario 12 de Octubre Madrid, 28041 Madrid, Spain., Barragan VV; Department of Radiation Oncology, Hospital Universitario de Badajoz, 06080 Badajoz, Spain., Nieto PV; Department of Radiation Oncology, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain., Martín JZ; Group of Translational Research in Cancer Immunotherapy, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga (UMA), Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain.; Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain., Couñago F; Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesiCare Madrid, 28002 Madrid, Spain.; Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesiCare Madrid, 28002 Madrid, Spain.; Department of Radiation Oncology, Emilio Vargas, GenesisCare Madrid, 28002 Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Exploration of targeted anti-tumor therapy [Explor Target Antitumor Ther] 2023; Vol. 4 (5), pp. 1082-1094. Date of Electronic Publication: 2023 Oct 30.
DOI:	10.37349/etat.2023.00182
Abstrakt:	Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antineoplastic therapy and supportive treatments. Certain similarities have been described in the physiopathology of coronavirus disease 2019 (COVID-19) and lung cancer (LC) that may explain the higher probability of these patients of developing a more serious disease with more frequent hospitalizations and even death, especially with the addition of smoking, cardiovascular and respiratory comorbidities, old age and corticosteroids use. Pre-existing lesions and cancer therapies change the normal architecture of the lungs, so diagnostic scales such as COVID-19 Reporting and Data System (CO-RADS) are of vital importance for a correct diagnosis and patient homogenization, with a high inter-observer correlation. Moreover, anticancer treatments have required an adaptation to reduce the number of visits to the hospital [hypofractionated radiotherapy (RT), larger intervals between chemotherapy cycles, delay in follow-up tests, among others]. In a way, this has also caused a delay in the diagnosis of new cancers. On the other hand, vaccination has had a positive impact on the mortality of these patients, who maintain a similar seroprevalence to the rest of the population, with a similar impact in mortality. Competing Interests: The authors declare that they have no conflicts of interest. (© The Author(s) 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu